Further, while efforts are made to diversify certain of our sources of components and materials, in certain instances there is only a sole source or supplier with no alternatives yet identified.Even claims without merit could subject us to adverse publicity and require us to incur significant legal fees.The pharmaceutical and medical products industries are competitive and subject to complex market dynamics and varying demand levels.Competition is primarily focused on cost-effectiveness, price, service, product performance, and technological innovation.Our facilities must be approved and licensed prior to production and remain subject to inspection from time to time thereafter.However, the impact of such changes and related expenses are difficult to estimate in advance.Finally, to the extent COVID-19 adversely affects our operations and global economic conditions more generally, many of the other risks described in this“ Risk Factors” section may be heightened.If our competitors develop more effective or affordable products or achieve earlier patent protection or product commercialization than we do, our business, financial condition and operations will likely be negatively affected.We manufacture our products in approximately 50 manufacturing facilities around the world.There is substantial competition in the product markets in which we operate.There remains some uncertainty regarding aspects of the implementation of the 2017 Tax Act that could potentially have adverse impacts on us.We generate the majority of our revenue and profit outside the United States.We will also look to unlock additional value through strategic capital deployment.Refer to Note 2 in Item 8 of this Annual Report on Form 10-K for additional information regarding the acquisition of Seprafilm.Refer to Note 2 in Item 8 of this Annual Report on Form 10-K for additional information regarding the acquisition of Cheetah.Refer to Note 2 in Item 8 of this Annual Report on Form 10-K for additional information regarding the acquisition of the Recothrom and Preveleak products.Refer to Note 4 in Item 8 of this Annual Report on Form 10-K for further information regarding these asset impairments.Refer to Note 10 in Item 8 of this Annual Report on Form 10-K for further information regarding these charges and related liabilities.Refer to Note 2 in Item 8 of this Annual Report on Form 10-K for further information regarding business development activities.Refer to Note 7 in Item 8 of this Annual Report on Form 10-K for further information.Refer to Notes 7 and 8 in Item 8 of this Annual Report on Form 10-K for further information regarding the investigation and stock compensation expense.Refer to Note 2 in Item 8 of this Annual Report on Form 10-K for further information.Refer to Note 7 in Item 8 of this Annual Report on Form 10-K for further information.Refer to Note 11 in Item 8 of this Annual Report on Form 10-K for further information regarding the lump-sum settlements and the pension annuitization.Refer to Note 5 in Item 8 of this Annual Report on Form 10-K for further information.Refer to Note 10 in Item 8 of this Annual Report on Form 10-K for additional information regarding our business optimization programs.Refer to Note 5 in Item 8 of this Annual Report on Form 10-K for a summary of the components of interest expense, net for 2020, 2019 and 2018.Refer to Note 11 in Item 8 of this Annual Report on Form 10-K for further information regarding pension and OPEB plan expenses.Refer to Note 12 in Item 8 of this Annual Report on Form 10-K for further information related to the 2017 Tax Act and the finalization of associated SAB 118 provisional adjustments.Refer to Note 8 in Item 8 of this Annual Report on Form 10-K for further information regarding our stock repurchases.Refer to Note 16 in Item 8 of this Annual Report on Form 10-K for additional details regarding our segments.Refer to Note 2 in Item 8 of this Annual Report on Form 10-K for further information about our significant acquisitions and other arrangements.Refer to Note 5 and Note 6, respectively, in Item 8 of this Annual Report on Form 10-K for further discussion regarding our debt instruments outstanding and finance lease obligations at December 31, 2020.For a discussion of our significant off-balance sheet arrangements, refer to Note 14 in Item 8 of this Annual Report on Form 10-K for information regarding receivable transactions, and Note 2 and Note 7 in Item 8 of this Annual Report on Form 10-K regarding joint development and commercialization arrangements, indemnifications and legal contingencies.Refer to Note 14 and Note 15 in Item 8 of this Annual Report on Form 10-K for further information regarding our financial instruments and hedging strategies.41 CHANGES IN ACCOUNTING STANDARDSRefer to Note 1 in Item 8 of this Annual Report on Form 10-K for information on changes in accounting standards.Our key assumptions are listed in Note 11 in Item 8 of this Annual Report on Form 10-K. The most critical assumptions relate to the plans covering U. S. and Puerto Rico employees, because these plans are the most significant to our consolidated financial statements.Refer to Note 12 within Item 8 of this Annual Report on Form 10-K for further information.Refer to Item 1A of this Annual Report on Form 10-K for additional discussion of regulatory matters and how they may impact us.Use of the words“ may,”“ will,”“ would,”“ could,”“ should,”“ believes,”“ estimates,”“ projects,”“ potential,”“ expects,”“ plans,”“ seeks,”“ intends,”“ evaluates,”“ pursues,”“ anticipates,”“ continues,”“ designs,”“ impacts,”“ affects,”“ forecasts,”“ target,”“ outlook,”“ initiative,”“ objective,”“ designed,”“ priorities,”“ goal,” or the negative of those words or other similar expressions is intended to identify forward-looking statements that represent our current judgment about possible future events.